CervoMed jumps on dementia drug trial data
28/07/2025 15:12
Updates ** Shares of drug developer CervoMed CRVO.O rise 34% to $12 ** Co says its experimental drug, neflamapimod, significantly slowed disease progression in patients with dementia with Lewy bodies, the second most common form of dementia, based on 32-week extension data from its mid-stage trial ** The extension data comes after a setback last December, when the drug failed to meet primary and secondary goals in the same trial, dragging CRVO's shares by 79% ** Patients who took neflamapimod showed a 54% lower risk of their disease getting worse compared to those who did not take the drug, co says ** Neflamapimod also reduced blood markers that indicate brain cell damage ** CRVO plans to meet with FDA in Q4 2025 to discuss late-stage trials ** Including session move, stock up 418% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))